scholarly journals Polymorphisms in adiposity-related genes are associated with age at menarche and menopause in breast cancer patients and healthy women

2012 ◽  
Vol 27 (7) ◽  
pp. 2193-2200 ◽  
Author(s):  
Kyee-Zu Kim ◽  
Aesun Shin ◽  
Yeon-Su Lee ◽  
Sook-Young Kim ◽  
Yeonju Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Age At Menarche ◽  
Breast Cancer Patients ◽  
Healthy Women

scholarly journals Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Carlos Henrique F. Peiró ◽  
Matheus M. Perez ◽  
Glauco S. A. de Aquino ◽  
Jéssica F. A. Encinas ◽  
Luiz Vinícius de A. Sousa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Glucose Transporter ◽  
Carbonic Anhydrases ◽  
Breast Cancer Patients ◽  
Gene Expressions ◽  
Liquid Biopsies ◽  
Healthy Women ◽  
Diagnostic Potential ◽  
Laboratory Tool

AbstractIn tumor cells, higher expression of glucose transporter proteins (GLUT) and carbonic anhydrases (CAIX) genes is influenced by hypoxia-induced factors (HIF).Thus, we aimed to study the expression profile of these markers in sequential peripheral blood collections performed in breast cancer patients in order to verify their predictive potential in liquid biopsies. Gene expressions were analyzed by qPCR in tumor and blood samples from 125 patients and 25 healthy women. Differential expression was determined by the 2(−ΔCq) method. Expression of HIF-1α and GLUT1 in the blood of breast cancer patients is significantly higher (90–91 and 160–161 fold increased expression, respectively; p < 0.0001) than that found in healthy women. Their diagnostic power was confirmed by ROC curve. CAIX is also more expressed in breast cancer women blood, but its expression was detected only in a few samples. But none of these genes could be considered predictive markers. Therefore, evaluation of the expression of HIF-1α and GLUT1 in blood may be a useful laboratory tool to complement the diagnosis of breast cancer, in addition to being useful for follow-up of patients and of women with a family history of breast cancer.

scholarly journals Erratum to: Content of HLA-G+ T Cells in the Peripheral Blood from Healthy Women and Breast Cancer Patients

2016 ◽  
Vol 160 (4) ◽  
pp. 592-592
Author(s):  
E. O. Ostapchuk ◽  
Yu. V. Perfil’eva ◽  
Sh. Zh. Talaeva ◽  
N. A. Omarbaeva ◽  
N. N. Belyaev
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Healthy Women

scholarly journals A comparative study of selenium concentration and glutathione peroxidase activity in normal and breast cancer patients

2009 ◽  
Vol 12 (1) ◽  
pp. 59-63 ◽  
Author(s):  
Masoumeh Moradi ◽  
Mohammad Hassan Eftekhari ◽  
Abdolrasoul Talei ◽  
Abdolreza Rajaei Fard
Keyword(s):  
Breast Cancer ◽  
Glutathione Peroxidase ◽  
Cancer Patients ◽  
Selenium Concentration ◽  
Atomic Absorption Spectrophotometry ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Significant Difference ◽  
Gpx Activity ◽  
Control Study

AbstractObjectiveThe present study was undertaken to compare plasma Se values and glutathione peroxidase (GPX) activity in normal and breast cancer patients.DesignIn a case–control study, forty-five breast cancer patients and the same number of healthy women were randomly selected from their population. Se was measured in plasma by atomic absorption spectrophotometry and GPX activity in erythrocytes was measured using a standard spectrophotometric method.ResultsPlasma Se concentration in healthy women and breast cancer patients was in the normal range, with no statistically significant difference observed between the two groups (138·40 (sd 40·36) μg/l v. 132·15 (sd 35·37) μg/l, respectively). Erythrocyte GPX activity was significantly (P<0·01) higher in breast cancer patients (24·81 (sd 11·66) U/g Hb) compared with healthy women (20·29 (sd 4·24) U/g Hb).ConclusionThe present study indicated that Se deficiency was not a problem in the participants, and sufficient quantity of this element could increase GPX activity to have a protective effect against oxidative damage.

Identification and validation of plasma protein biomarker panels for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10621-10621
Author(s):  
Hyeong-Gon Moon ◽  
Un-Beom Kang ◽  
Wonshik Han ◽  
Seock-Ah Im ◽  
Dong-Young Noh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Plasma Protein ◽  
Multiple Reaction Monitoring ◽  
Breast Cancer Diagnosis ◽  
Reaction Monitoring ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Protein Signature

10621 Background: Multiple reaction monitoring-based mass spectrometry (MRM-MS) has the ability to perform a wide range of proteome analysis in a single experiment using a small volume of specimen. We aimed to develop a plasma protein signature for breast cancer diagnosis using the MRM-MS technology. Methods: Previously, we have identified lists of breast cancer-related proteins from various models of proteomic discovery including cancer plasma vs healthy plasma, cancer cell line secretome vs non-tumorigenic cell line secretome, cancer tissue vs normal tissue, and literature search. Based on these protein panels, total of 29 proteins were selected for further experiments. We verified and validated the protein signature in two independent cohorts of breast cancer patients and healthy women. Results: In the verification cohort of 80 breast cancer patients and 80 healthy women, MRM-MS showed significant differences in plasma concentration for 11 proteins. Among them, the difference was not significant for 4 proteins when the cases were limited to stage I and II patients. Based on p values and consistent expression level along the AJCC stages, we have created a plasma protein signature comprised of 3 plasma proteins. The 3 plasma protein signature effectively discriminated cancer and healthy cases with the AUC of 0.831 (sensitivity 78.7%, specificity 78.7%). The performance of the 3 plasma protein signature was validated in the cohort of 100 cancer patients and 100 healthy women. The accuracy of the 3 protein signature was still meaningful with the AUC of 0.746 and 0.797 for all stages and stage I or II patients, respectively. Conclusions: The 3 plasma protein signature for breast cancer diagnosis, developed by the MRM-MS technology, showed promising results in the present study.

scholarly journals Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women

Maturitas ◽  
2018 ◽  
Vol 116 ◽  
pp. 83-88 ◽  
Author(s):  
Marta Pineda-Moncusí ◽  
Miguel Angel Garcia-Perez ◽  
Abora Rial ◽  
Guillem Casamayor ◽  
Maria Lourdes Cos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Vitamin D Levels

scholarly journals Each pregnancy linearly changes immune gene expression in the blood of healthy women compared with breast cancer patients

2018 ◽  
Vol Volume 10 ◽  
pp. 931-940 ◽  
Author(s):  
Eiliv Lund ◽  
Aurelie Nakamura ◽  
Igor Snapkov ◽  
Jean-Christophe Thalabard ◽  
Karina Standahl Olsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Immune Gene ◽  
Breast Cancer Patients ◽  
Immune Gene Expression ◽  
Healthy Women

OOPHORECTOMY AND CORTISONE TREATMENT AS A METHOD OF ELIMINATING OESTROGEN PRODUCTION IN PATIENTS WITH BREAST CANCER

1964 ◽  
Vol 47 (1) ◽  
pp. 15-26 ◽  
Author(s):  
Bengt H. Persson ◽  
Lars Risholm
Keyword(s):  
Breast Cancer ◽  
Urinary Excretion ◽  
Postmenopausal Women ◽  
Cancer Patients ◽  
Surgical Procedures ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Adequate Dose ◽  
Secondary Rise ◽  
Excretion Level

ABSTRACT The urinary excretion of oestrone, oestradiol-17β, oestriol, and 17-hydroxycorticosteroids has been estimated in 55 premenopausal and 91 postmenopausal women with breast cancer at various stages of the disease before therapy. The depletion of oestrogen excretion caused by oophorectomy combined with cortisone treatment was studied in the patients with metastasising breast tumours (32 premenopausal and 56 postmenopausal subjects). Patients with disseminating breast cancer excreted significantly larger quantities of oestriol than healthy women of the same age, whether preor postmenopausal. The excretion of oestrone and oestradiol-17β was similar in cancer patients and healthy women of corresponding age. Oophorectomy reduced the oestrogen excretion not only in premenopausal subjects but also in quite a number of postmenopausal patients, particularly in those who were still excreting significant amounts of oestrogens. This decrease in the oestrogen output was transient and was followed by a compensatory increase, possibly of adrenal origin. Cortisone administered within a month after the oophorectomy at a dosage of 50 mg per day rapidly depressed the secondary rise in the oestrogen output to a level of about 4 to 5 μg/24 h irrespective of the age of the patient. This excretion level was unchanged as long as cortisone was given in an adequate dose, but increased rapidly when the cortisone treatment was discontinued. Oophorectomy combined with adequate cortisone treatment seems to offer an alternative to the extensive surgical procedures undertaken to eliminate oestrogen production in breast cancer patients.

scholarly journals Vitamin D pathway modulation in Caucasian case series of healthy women and breast cancer patients

2015 ◽  
Vol 26 ◽  
pp. vi19
Author(s):  
L. Mercatali ◽  
N. Masalu ◽  
A. Bongiovanni ◽  
A. Pangan ◽  
R. Tedaldi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Case Series ◽  
Breast Cancer Patients ◽  
Healthy Women
Sign in / Sign up

Export Citation Format

Share Document